Garenoxacin mesylate is a Small Molecule owned by FUJIFILM Toyama Chemical, and is involved in 7 clinical trials, which were completed.

Garenoxacin mesylate is a topoisomerase IV, DNA gyrase inhibitor. It works by inhibiting bacterial DNA gyrase (main target in gram negative bacteria) and topoisomerase IV (main target in gram +ve bacteria). The major mechanism of action requires cell division quinolones also have other mechanisms of action which result in them being active against bacteria that are not actively replicating. The cross outer membrane of gram negative bacteria via porins affinity for bacterial target enzymes is 1000 times that for equivalent human enzymes minimum inhibitory concentration (MIC) is increased in the presence of magnesium and in acid environments (pH <6). It acts by inhibition of a metabolic pathway and disruption of bacterial membrane structure.

The revenue for Garenoxacin mesylate is expected to reach a total of $99m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Garenoxacin mesylate NPV Report.

Garenoxacin mesylate is originated and owned by FUJIFILM Toyama Chemical. Astellas Pharma and Taisho Pharmaceutical Holdings are the other companies associated in development or marketing of Garenoxacin mesylate.

Garenoxacin mesylate Overview

Garenoxacin mesylate (Geninax) is a quinolone derivative, acts as  antibiotic or antibacterial agent. It is formulated as film-coated tablets for oral route of administration. It is indicated for the treatment of infections such as pharngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, chronic respiratory lesions secondary infection, otitis media and sinusitis caused by susceptible microrganisms.

Garenoxacin mesylate (Geninax, T-3811) was under development for the treatment of bacterial infections in Japan as injectable formulation, and in EU and US as oral and injectable formulations.

Astellas Pharma Overview

Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY1,296,163 million for the fiscal year ended March 2022 (FY2022), an increase of 3.7% over FY2021. In FY2022, the company’s operating margin was 12.4%, compared to an operating margin of 11.7% in FY2021. In FY2022, the company recorded a net margin of 9.6%, compared to a net margin of 9.7% in FY2021. The company reported revenues of JPY380,394 million for the second quarter ended September 2022, a decrease of 0.4% over the previous quarter.

Quick View – Garenoxacin mesylate

Report Segments
  • Innovator (NME)
Drug Name
  • Garenoxacin mesylate
Administration Pathway
  • Oral
  • Parenteral
Therapeutic Areas
  • Ear Nose Throat Disorders
  • Infectious Disease
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.